GSK’s Promising Phase 3 Study on Multiple Myeloma Treatment: A Market Game Changer?

GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.

GlaxoSmithKline (GSK) is conducting a Phase 3 study titled ‘A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)’. The study aims to determine if the BRd combination can prolong progression-free survival and improve minimal residual disease negative status compared to the DRd combination in patients with newly diagnosed multiple myeloma.

The interventions being tested include Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the experimental arm, and Daratumumab, Lenalidomide, and Dexamethasone in the active comparator arm. These treatments are designed to manage multiple myeloma in patients who cannot undergo stem cell transplantation.

This interventional study follows a randomized, parallel assignment model with no masking, focusing primarily on treatment. Participants are allocated to either the experimental or comparator group to evaluate the efficacy of the interventions.

The study began on November 6, 2024, with the last update submitted on August 26, 2025. These dates are crucial as they mark the progress and current status of the study, which is still recruiting participants.

The outcome of this study could significantly impact GSK’s market position, potentially boosting its stock performance if the results are favorable. Investors should watch for updates, as successful results could enhance GSK’s competitive edge in the oncology market, particularly in the treatment of multiple myeloma.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.